Benefits and Harms of Levothyroxine/liothyronine vs. Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-analysis.

Abstract

BACKGROUND\nCombined therapy with levothyroxine/liothyronine (L-T4/L-T3) has garnered attention among clinicians and patients as a potential treatment alternative to levothyroxine (L-T4) monotherapy. The objective of this study was to compare the benefits and harms of L-T4/L-T3 combined therapy and L-T4 monotherapy for patients with hypothyroidism.\n\n\nMETHODS\nA systematic search in MEDLINE, Scopus, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials was performed by a librarian from inception date until September 2020. Randomized clinical trials and quasi-experimental studies comparing combined therapy (L-T4/L-T3) versus monotherapy (L-T4) for adult patients with hypothyroidism were considered for inclusion. Independent data extraction was performed by paired reviewers. A meta-analysis comparing standardized mean differences of the effect of each therapy was performed on clinical outcomes and patient preferences. Proportions of adverse events and reactions were assessed narratively.\n\n\nRESULTS\nA total of 1398 references were retrieved from which 18 fulfilled inclusion criteria. Results supported by evidence at low-to-moderate certainty evidence did not display a difference in treatment effect between therapies on clinical status, quality of life, psychological distress, depressive symptoms, and fatigue; all measured with standardized questionnaires. Furthermore, meta-analysis of patient preferences revealed higher proportions of choice for combined therapy (43%) when compared to monotherapy (23%) or having no preference (30%). When evaluating treatment adverse events or adverse reactions, similar proportions were observed between treatment groups; meta-analysis was not possible.\n\n\nCONCLUSIONS\nThe available evidence at low-to-moderate certainty demonstrates that there is no difference in clinical outcomes between L-T4/L-T3 combined therapy and L-T4 monotherapy for treating hypothyroidism in adults, except for a higher proportion of patient preferring combined therapy. Adverse events and reactions appear to be similar across both groups, however this observation is only narrative. These results could inform shared decision-making conversations between patients with hypothyroidism and their clinicians. PROSPERO Registration ID: CRD42020202658.